secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-01-18T23:59:59+00:00
Accession:  0001818331-22-000010
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 agrees to acquire GeneDx from OPKO for $150M cash + 80M shares; $200M PIPE at $4.00/share
--------------------------------------------------------------------------------

- Total consideration: $150M cash + 80M Sema4 shares + up to $150M in revenue-based milestones.
- GeneDx CEO Katherine Stueland will become Co-CEO of Sema4 post-close; Jason Ryan named Executive Chair.
- PIPE of $200M (50M shares at $4.00/share) from institutional investors, including existing holders.
- Closing expected in H1 2022, subject to stockholder approval, HSR, and other customary conditions.
- OPKO and certain holders subject to 1-year lock-up on stock consideration; support agreements for voting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000010/0001818331-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000010/smfr-20220114.htm
  HTML page:      https://secwatch.observer/filing/0001818331-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer